文献速递白血病

ETV6::RUNX1 急性淋巴细胞白血病:治愈需要多少治疗?

ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?
PubMed 文献 · Leukemia · 2024-06-06

该文汇总八项国际试验的累计药物剂量与强度以刻画治愈所需治疗,并对5年与10年生存结局做Meta分析。结果显示,在低危与中危组中,部分试验组未显示研究间异质性,而另一试验组存在统计学异质性;使用更高累计剂量和强度的门冬酰胺酶及糖皮质激素与长春新碱脉冲的试验5年无事件生存更好但总生存相似。

要点

  • 八项国际试验的5年生存率均超过95%。
  • 试验A组低危与中危未显示研究间异质性。
  • 试验B组低危与中危存在统计学异质性。

核心结论

  • 基于治疗强度不同但结局相似,未来试验应探究ETV6::RUNX1急性淋巴细胞白血病可降阶梯治疗的程度。

研究设计与样本

  • 对八项国际试验进行累计药物剂量与强度比较,并按风险组分布将试验分为两组:试验A组低危患者约70%(范围63.5-75%),试验B组低危患者约45%(范围38.7-52.7%)。
  • 进行Meta分析以综合总结5年和10年生存结局。

主要发现

  • Meta分析未显示试验A组低危和中危研究间存在异质性,尽管治疗强度不同。
  • 试验B组低危和中危存在统计学异质性。
  • 使用更高累计剂量和强度门冬酰胺酶及糖皮质激素与长春新碱脉冲的试验显示更好的5年无事件生存但总生存相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent trials show 5-year survival rates >95% for ETV6::RUNX1 Acute Lymphoblastic Leukemia (ALL). Since treatment has many side effects, an overview of cumulative drug doses and intensities between eight international trials is presented to characterize therapy needed for cure. A meta-analysis was performed as a comprehensive summary of survival outcomes at 5 and 10 years. For drug dose comparison in non-high risk trial arms, risk group distribution was applied to split the trials into two groups: trial group A with ~70% (range: 63.5-75%) of patients in low risk (LR) (CCLSG ALL2004, CoALL 07-03, NOPHO ALL2008, UKALL2003) and trial group B with ~45% (range: 38.7-52.7%) in LR (AIEOP-BFM ALL 2000, ALL-IC BFM ALL 2002, DCOG ALL10, JACLS ALL-02). Meta-analysis did not show evidence of heterogeneity between studies in trial group A LR and medium risk (MR) despite differences in treatment intensity. Statistical heterogeneity was present in trial group B LR and MR. Trials using higher cumulative dose and intensity of asparaginase and pulses of glucocorticoids and vincristine showed better 5-year event-free survival but similar overall survival. Based on similar outcomes between trials despite differences in therapy intensity, future trials should investigate, to what extent de-escalation is feasible for ETV6::RUNX1 ALL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Østergaard A, Fiocco M, de Groot-Kruseman H, et al. ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure? Leukemia. 2024. PMID: 38844578. doi:10.1038/s41375-024-02287-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。